Arginetix and Immune Control Merge to Form Corridor Pharmaceuticals

Arginetix, Inc. and Immune Control Inc. today announced their merger to form Corridor Pharmaceuticals, Inc., which will develop novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension (PAH). Corridor will develop treatments based on the first-in-class arginase inhibition platform developed by Arginetix, and Immune Control’s serotonin antagonist technology. Gary Lessing, formerly the CEO of Arginetix, will serve as CEO of Corridor, and Stephen Roth, Ph.D., formerly CEO of Immune Control, will serve as executive vice chairman of the board of directors. […]

Read More…